☸️ SAIMSARA — Public Sessions

Seborrheic dermatitis is more than dandruff or simple fungal overgrowth: this evidence map shows a recurrent inflammatory disease shaped by Malassezia dysbiosis, barrier/lipid dysfunction, immune activation, Staphylococcus signals, and psychosocial burden. The full SAIMSARA evidence map is worth reading because it separates stronger treatment signals — ketoconazole, ciclopirox, selenium disulfide, calcineurin inhibitors, isotretinoin, roflumilast foam, and barrier repair — from emerging or heterogeneous findings across 706 original studies.

Biofield therapies show their clearest signal not as curative medicine, but as low-risk supportive care for stress, anxiety, pain, burnout, and oncology-related symptom burden, while sham-controlled null findings and retracted evidence sharply limit certainty. The full SAIMSARA evidence map is worth reading because it separates plausible symptom-focused signals from weak, heterogeneous, non-replicable, or overstated claims across Reiki, Healing Touch, Johrei, distant healing, and laboratory biofield models.

Endovascular hemodialysis AVF care is no longer only a rescue technique: the mapped evidence shows a full access-life-cycle strategy, from percutaneous creation and assisted maturation to repeated salvage of stenosed, immature, or thrombosed fistulas. The full SAIMSARA evidence map gives a structured, reference-linked view of which techniques work, where patency fails, how often reintervention is needed, and which patient or lesion phenotypes may benefit most.

AI clinical scribes can reduce documentation burden, but this evidence map shows why they are not yet safe as autonomous note-writers: hallucinations, omissions, acoustic failures, EHR friction, consent gaps, and medicolegal uncertainty remain central limitations. The full SAIMSARA evidence map gives a structured, reference-linked view of where ambient AI documentation works, where it fails, and what clinicians, vendors, and health systems must verify before scaling it.

Medical machine translation may look fluent, but this review shows where it still breaks: semantic precision, cultural nuance, audience adaptation, and high-stakes clinical reliability. The full read is worth it because it separates the real strengths of MT in constrained tasks from the specific failure modes that still make expert human oversight essential.

This review shows that the strongest medication signal in AAA is not true aneurysm-shrinking therapy, but better survival: statins and antiplatelet treatment repeatedly track with lower long-term mortality, while most putative growth-modifying drugs still rest on mixed or observational evidence. It maps where medical AAA care is already actionable today, where metformin and other candidates remain uncertain, and which pharmacologic strategies may genuinely change aneurysm biology rather than just cardiovascular risk.

PAD is not failing for lack of options — it is failing because the right options are too often used in isolation, too late, or not at all. This review shows where the strongest treatment signals truly are, from rivaroxaban-plus-aspirin and exercise therapy to IVUS-guided revascularization, and why real progress depends on combining them into one strategy.

Popliteal venous aneurysm is rare, but the mapped evidence shows why it matters: recurrent PE, saccular morphology, thrombus burden, and size thresholds above 20–25 mm repeatedly point toward clinically relevant embolic risk. The full SAIMSARA evidence map gives humans and AI agents a structured, reference-linked view of presentation patterns, operative strategies, patency outcomes, anticoagulation limits, and unresolved thresholds for intervention.

Personalized healthcare is no longer just a promise of precision medicine — this review shows where it is already becoming clinically real, from AI prediction and pharmacogenomics to wearable monitoring and tailored care pathways. Across more than 1,300 original studies, the paper maps which personalized strategies are truly improving diagnosis, chronic disease control, and care delivery — and where the field still risks failing on fairness, infrastructure, and real-world implementation.

Combat sports are not only contests of power, technique, and mental resilience — they are also defined by a dangerous hidden physiology of rapid weight loss, dehydration, concussion, and cumulative trauma. This review maps where performance advantage ends and measurable athlete harm begins, highlighting why modern combat-sport medicine must integrate weight-cut monitoring, concussion protocols, ringside screening, and female-athlete surveillance.

This paper shows that coffee is not simply “good” or “bad” for health: moderate intake is repeatedly linked with lower risks of stroke, dementia, diabetes, and death, while higher intake and certain coffee types can also carry harm signals. Read the full paper to see where the benefits look most convincing, where the evidence becomes conflicting, and which patients may need more caution than the usual “2–3 cups a day” message suggests.

This paper shows that Rutherford classification is not just a staging label in acute limb ischemia, but one of the clearest bedside signals for who can still be saved, who needs immediate action, and where delay turns threatened limb into loss. The full read is worth it because it separates the real prognostic and treatment signal from observational noise—showing where endovascular therapy performs well, where Rutherford IIb becomes the decisive tipping point, and why timing still matters even within the same severity class.